Intravenous injection of microvesicle-delivery miR-130b alleviates high-fat diet-induced obesity in C57BL/6 mice through translational repression of PPAR-γ

We have shown previously that microvesicle (MV)-delivered miR-130b (miR-130b-MV) is able to target PPAR-γ and subsequently reduce the lipid accumulation in vitro. However, the in vivo effect of miR-130b on fat deposition and glucose homeostasis remains unknown. Three-week-old C57BL/6 mice were fed a high-fat diet for 8 weeks and then intravenously injected with MV-packaged scrambled control microRNA (miRNA) or miR-130b every other day for 10 days. Glucose tolerance test was performed and body weight, epididymal fat weight, as well as the expression of lipid metabolic genes were determined. We showed that mice fed on high-fat diet for 8 weeks demonstrated significantly higher body weight, elevated blood glucose and impaired glucose tolerance. miR-130b-MV injection significantly reduced body weight and epididymal fat weight and partly restored glucose tolerance. miR-130b expression was significantly increased in the epididymal fat after miR-130b-MV injection while the protein content of its target gene PPAR-γ was significantly suppressed, together with a significant up-regulation of the lipolysis genes, hormone sensitive lipase, monoglyceride lipase and leptin. Moreover, miR-130b-MV injection increased the expression of miR-378a and miR-378-3p that are reported to participate in the regulation of fat deposition. Our results indicate that miR-130b-MV is able to reduce the epididymal fat deposition and partly restore glucose tolerance, through translational repression of PPAR-γ in a high-fat diet-induced obese mouse model.


Background
Obesity is a major risk factor for the development of type II diabetes (T2DM), cardiovascular diseases, and some types of cancer [1][2][3][4][5]. Searching for more efficient and safe approaches to prevent and treat obesity has been the focus of intensive research. Peroxisome proliferator activated receptor gamma (PPAR-γ) is a ligand activated transcription factor which is regarded as a master regulator of fat deposition [6][7][8]. Previous studies have shown that activation or over-expression of PPAR-γ can stimulate lipogenesis and adipogenesis [1], while down-regulation of PPAR-γ decreases fat mass in mice [9][10][11][12][13]. Therefore, PPAR-γ is considered as a therapeutic target for the treatment of obesity.
MicroRNAs (miRNAs) are small non-coding RNAs which regulate gene expression through mRNA degradation and/or translational repression [14]. Numerous studies have demonstrated that some miRNAs can inhibit PPARγ expression and suppress adipogenesis and lipogenesis. Both miR-302a and miR-27a are reported to inhibit adipogenic differentiation and lipid accumulation in 3T3-L1 mouse adipocytes [15] and human multipotent adiposederived stem cells [16] by down-regulating PPAR-γ expression. miR-130 has been shown to strongly reduce adipogenesis by repressing PPAR-γ biosynthesis in human primary preadipocytes and 3T3-L1 mouse adipocytes [17]. These findings suggest that miRNAs may be used as an effective therapy for the treatment of obesity. However, exogenous miRNAs without appropriate protection or modifications can be quickly degraded by RNases that are abundant in the blood [18]. Therefore, the stability of exogenous miRNAs is one of the primary concerns with respect to clinical application [19].
Microvesicles (MVs) are a heterogeneous population of membrane-covered vesicles ranging from 100 nm to 1 μm in diameter, being secreted by almost all types of cells in vivo and in vitro under both normal and pathological conditions [20][21][22][23]. MVs are able to protect, transport and deliver bioactive contents, including miRNAs [24], from parent cells to cells of other origins [25,26]. Recently, we demonstrated that miR-130b can be packaged into MVs and delivered to the recipient primary cultured porcine adipocytes to reduce lipid accumulation in vitro by inhibiting PPAR-γ expression [27] . Nevertheless, it remains unknown whether MV-shuttled miR-130b can modulate fat deposition through targeting PPAR-γ in vivo.
Therefore, in the present study, we tested anti-obesity efficacy of MV-packaged miR-130b on a high-fat dietinduced C57BL/6 mouse model. miR-130b was packaged into MV by HeLa-229 cells transfected to over-express exogenous miR-130b. MV-packaged miR-130b was isolated from the culture media through ultracentrifugation and was injected intravenously to the obese mice. We show that miR-130b was delivered to the epididymal fat tissue and significantly decreased the fat deposition, which was associated with a significant down-regulation of PPAR-γ protein content and an activation of lipolytic genes. Our results provide the preliminary evidences that MV-mediated delivery of miR-130b is able to reduce fat deposition in a high-fat diet-induced obese model.

Plasmid construction
The precursors of miR-130b (89 bp) and the negative control miRNA (Scrambled control, miR-SC) were synthesized by Life Technologies Inc., based on the sequence information from miRNA precursors (www.mirbase.org) and the requirements for pSilencer 3.1-H1 siRNA expression vector (Ambion, Austin, TX, USA). Precursors of miR-130b and miR-SC were produced by annealing the upstream and downstream (50 μmol/L each) miRNA precursor sequences ( Table 1). The 50 μL reaction mix was incubated in 96-well plates at 95°C for 2 min, and subjected to touchdown PCR. During this procedure the temperature was decreased 0.1°C every 8 s until it reached 25°C. The PCR products were subcloned into pSilencer 3.1-H1 siRNA expression vector using BamHI and HindIII restriction endonucleases (Life Technologies Inc.).
Cell culture, miR-130b transfection and microvesicle isolation Approximately 3 × 10 5 /cm 3 HeLa-229 cells were seeded in 150 mm cell culture dish and grown in DMEM/F-12 media supplemented with 15 mmol/L NaHCO 3 , 100 IU/mL penicillin, 100 IU/mL streptomycin, and 10 % FBS at 37°C in a 5 % CO 2 , water-saturated incubator. When the cells reached 90-95 % confluence, plasmids of 50 μg miR-130b and 50 μg miR-SC were transfected separately with Lipofectamine 2000 (Life Technologies Inc.), according to the manufacturer's instructions. The transfected cells were incubated at 5 % CO 2 and 37°C. Four hours later, the transfection medium was changed to DMEM/F-12 containing 10 % MVs-free FBS prepared by ultracentrifugation and filtration [28]. Cells were harvested 24 h after transfection and the medium was collected.
MVs were isolated from the medium by differential centrifugation according to previously published methods [29]. Briefly, 18 mL media mixture from six dishes was subjected to serial centrifugation. Initial centrifugation was undertaken at 300 g for 10 min followed by 1200 g for 10 min and 10,000 g for 20 min, by this process dead cells and other debris were removed. Then the resulting supernatant was filtered through 0.22 μm filters (Millipore, Billerica, MA, USA) into Beckman Quick seal tubes. Ultracentrifugation was performed at 110,000 g for 2 h using a 70Ti rotor (Beckman Coulter, Brea, CA, USA). All steps were performed at 4°C. MVs were collected from the pellets and re-suspended in FBS-free media for subsequent assay. The Bicinchoninic acid (BCA) method was used to quantify the total protein concentration in MVs preparations.

Animals and diets
All procedures involving laboratory animal use were approved by the Animal Ethics Committee of Nanjing Agricultural University, with the project number 2012CB124703. The slaughter and sampling procedures complied with the "Guidelines on Ethical Treatment of Experimental Animals" Three-week-old male specific pathogen-free (SPF) C57BL/ 6 mice weighing 9~10 g were obtained from the Comparative Medicine Center of Yangzhou University (Yangzhou, China, certificate of quality is SCXK (Su) 2012-0004) and fed in the Laboratory Animal Center of Jiangsu Province Integrative Medicine Hospital. The mice were housed in standard cages (33 × 23 × 12 cm, five mice/cage), maintained under controlled conditions (22 ± 0.5°C, 50 ± 5 % relative humidity, 12-h/12-h dark/light cycle) with free access to both food and water.
After 7-day adaptation, thirty-six mice were randomly divided into two groups as follows: (1) the control group (MD10% fat group, n = 12) fed with normal fat diet (MD12031, 10 % fat); (2) the high fat group (MD45% fat group, n = 24) fed with high-fat diet (MD12032, 45 % fat). Both control and high fat diets were purchased from Medicience Ltd. (Yangzhou, China). The diets were replaced every 2 days to prevent oxidization of the fats in diets. After 8 weeks, the body weight was recorded and the glucose tolerance test was performed to confirm the successful establishment of the obese mouse model.
Then, we divided the obese mice randomly into two groups: (1) the control group injected with miR-SC-MV (HF-SC-MV); (2) the treated group injected with miR-130b-MV (HF-130b-MV). The mice were injected every other day for 10 days. During the 10 days of treatment, the mice in both groups were still fed high-fat diet.

Oral glucose tolerance test (OGTT)
After 10 h fasting (from 8:30 in the morning till 18:30 in the afternoon), the mice were given glucose at 2.5 g/kg body weight by intraperitoneal injection. The blood glucose levels before glucose injection (0 min) and 15, 30, 60, 90, 120 min after glucose injection were determined.

Preparation of blood and epididymal fat tissue
After ten days of treatment, the mice were fasted for 10 h and the body weight was recorded. Then the blood

RNA isolation and mRNA quantification
Total RNA was isolated from liver using Trizol reagent (Life Technologies Inc.), according to the manufacturer's instructions. Concentration of the extracted RNA was measured using a NanoDrop-1000 spectrophotometer. RNA integrity was confirmed by denaturing agarose electrophoresis, and DNA contamination was evaluated by PCR using isolated RNA as template with the primers of 18s. M-MLV (Promega, Madison, WI, USA) and dN6 random primer (Takara, Kyoto, Japan) were used to synthesize cDNA from 2 μg of total RNA from each sample according to manufacturer's instructions. Three reference genes (PPIA, GAPDH and 18s) were tested and the mRNA abundances showed no difference between the two groups, and at last PPIA was chosen as a reference gene. Real-time PCR was performed in Mx3000P (Stratagene, Palo Alto, CA, USA). All primers used for this experiment were listed in Table 1.

miRNAs real-time PCR quantification
Total RNA was treated with RNase-free, DNase I (TaKaRa). The total RNA (4 μg) was polyadenylated by poly (A) polymerase at 37°C for 1 h in a 20 μL reaction mixture using a Poly (A) tailing kit (AM1350, Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. The polyadenylated RNA was then dissolved and reverse transcribed using the poly (T) adapter.
Real-time PCR was performed, in triplicate, using the SYBR green qPCR master mix reagent (Takara) with a miRNA-specific forward primer and a universal reverse primer that is complementary to part of the poly (T) adapter sequence. Since no validated reference gene was available for pig miRNAs, a random DNA oligonucleotide was added to RNase-free DNase I-treated total RNA samples before polyadenylation, as an exogenous reference, to normalize the expression of miRNAs. The sequences of all the mature miRNAs, the poly (T) adapter and the exogenous reference gene used in the present study are listed in Table 2.

Determination of PPAR-γ protein content
Total protein was extracted from the epididymal adipose tissue and the protein concentration was measured using a BCA protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Protein extracts (30 μg) were used for electrophoresis on a 12 % SDS-PAGE gels. Western blot analysis for detecting PPAR-γ was undertaken according to the protocols provided by the manufacturer. GAPDH was used as a reference.

Statistical analysis
All data are presented as means and standard errors (± SEM). For oral glucose tolerance test, the general linear model (univariate) was conducted to evaluate the effects of miR-130b-MV injection and the injection time point, as well as their interactions. The differences between two groups were tested using one-way analysis of variance

Results
Establishment of high-fat diet-induced obese mouse model C57BL/6 obese mouse model was successfully established after feeding high-fat diet ad libitum for 8 weeks (Fig. 1). The experimental design for establishing the obese mice model is depicted in a flow chart (Fig. 1a). The body weight was significantly higher (P < 0.01) in high-fat diet group (Fig. 1b-c) with significantly increased (P < 0.05) body weight gain (Fig. 1d). The oral glucose tolerance test (OGTT) demonstrated impaired glucose tolerance in high-fat diet group as compared with the control group (Fig. 1e), which was indicated by significantly increased (P < 0.001) area under the blood glucose-time curve (AUC) (Fig. 1f ).

miR-130b-MV partly restored glucose tolerance
To determine the effects of miR-130b-MV injection on the glucose tolerance, OGTT was performed (Fig. 2). Blood glucose concentrations in miR-130b-MV-injected mice were significantly reduced (P = 0.003) after the intravenous injection of glucose (2.5 g/kg body weight) when compared with miR-SC-MV-injected mice (Fig. 2a). In addition, miR-130b-MV injection tended to reduce (P = 0.057) the AUC when compared with miR-SC-MVinjected mice (Fig. 2b). The above results suggest that intravenous injection of miR-130b-MV partly restored the glucose tolerance caused by high-fat diet.

miR-130b-MV reduced body weight and epididymal fat weight
The protocol of MV injection via tail vein is depicted in the flow chart (Fig. 3a). We delivered miR-130b-MV to assess the anti-obesity effect of miR-130b in vivo. The HeLa-229 cell expresses very low level of miR-130b [27], so it was chosen to serve as a carrier host for the overexpression of exogenous miR-130b. HeLa-229 cells were transfected with the miR-130b over-expression plasmid, while plasmid over-expressing miR-SC was also transfected to serve as a negative control. MVs containing miR-130b and miR-SC were purified from the supernatant of transfected cells and RT-PCR verified the package of significantly higher levels of miR-130b in miR-130b-MV preparations (Fig. 3b). miR-130b-MV and miR-SC-MV preparations were injected via tail vein into the obese mice of treatment and control groups respectively every other day for 10 days. The phenotypic changes in body size and fat deposition are shown in Fig. 3c-e, which indicate obviously reduced body weight and the epididymal fat mass in mice treated with miR-130b-MV. Quantitatively, miR-130b-MV significantly reduced the body weight (P < 0.01), the epididymal fat weight (P < 0.05) (Fig. 3f) and the muscle weight (P < 0.05), but not the liver weight. Furthermore, the epididymal fat weight relative to the body weight tended to be lower (P = 0.063) (Fig. 3g) in miR-130b-MV group when compared with miR-SC-MV group. The relative muscle weight was not different, yet the liver weight relative to the body weight was significantly higher (P < 0.05) in miR-130b-MV group compared with miR-SC-MV counterparts ( Table 3).

miR-130b-MV affected mRNA expression of lipid metabolic genes in epididymal fat
Injection of miR-130b-MV affected the expression of lipid metabolic genes in the epididymal fat of high-fat dietinduced obese mice (Fig. 4). Hormone sensitive lipase (HSL) and monoacylglycerol lipase (MGL), the two lipolytic enzymes, as well as leptin, the appetite suppressing adipokine, were significantly up-regulated (P < 0.01) in the epididymal fat of high-fat diet-induced obese mice. The mRNA expression of adipose triglyceride lipase (ATGL) tended to be higher (P = 0.07) in miR-130b-MV-injected mice while the mRNA expression of leptin receptor was not affected.

Discussion
High-fat induced obese C57BL/6 mice have been widely used as a model for studying human visceral obesity because they represent the human simple obesity both metabolically and pathophysiologically [30][31][32] . In this study, feeding C57BL/6 mice with high-fat diet for 8 weeks significantly increased the body weight by over 20 %, indicating that the obese mice model was successfully established [33]. Furthermore, blood glucose concentration was also significantly increased, suggesting impaired glucose tolerance which is closely associated with obesity [34].
In our previous study, we demonstrated that miR-130b-MV was able to reduce the lipid deposition in porcine primary adipocytes in vitro by targeting PPAR-γ gene [27]. Here we provide the evidence that miR-130b-MV injection was effective to decrease body weight and reduce epididymal fat deposition in high-fat dietinduced obese mice in vivo, at least partly through the translational repression of PPAR-γ. This is in agreement with a previous observation that miR-150-MV injection suppressed its target c-Myb expression and enhanced cell migration in mice [35] . Similarly, it was reported that miR-143-MV injection via tail vein was able to suppress tumor growth in mice [36]. Although there have been several attempts to administer MV-shuttled miRNAs by intravenous injection, this study provides, to our knowledge, the first evidence that miRNA packaged in MVs has an anti-obesity efficacy in an in vivo animal model.
However, the safety of miR-130b-MV-mediated therapy for obesity has to be considered. In the present study, we inspected histologically the possible side effects of miR-130b-MV on other tissues, including liver, kidney, heart and spleen. No obvious pathological changes were observed (H&E results not shown). Based on the consideration that each miRNA may target multiple target genes and function through different pathways [37], we detected numerous biochemical and hormonal parameters in the plasma including ALT, AST, Tch, TG, glucose, HDLc, LDLc, IL-6, insulin, leptin, and TNF-α. Interestingly, none of these blood parameters showed significant change, except TG and glucose displayed a tendency of decrease. This indicates that the general metabolic homeostasis of the body was not disturbed by miR-130b-MV treatment. Moreover, GR, TNF-α, UCP-3, SCD-1, LDLR, and STAT3, in addition to PPAR-γ, are also predicted to be the target of miR-130b, yet the  Fig. 1 Establishment of high-fat diet-induced obese mouse model. a: Flow chart depicting the experimental design. Three-week-old C57BL/6 mice were fed with a normal fat diet (MD10% group) or a high fat diet (MD45% group) for 8 weeks. The obese mice model was confirmed by detecting body weight and OGTT. b: Body weight of C57BL/6 mice after feeding high-fat diet for 8 weeks. c: Phenotype of C57BL/6 mice. d: Changes in body weight in C57BL/6 mice during 8 weeks' high-fat diet feeding. e: Mean blood glucose levels following OGTT. f: Area under the blood glucose-time curve (AUC). MD10%, 10 % fat medicience diet, normal fat diet group; MD45%, 45 % medicience diet, high-fat diet group; OGTT, oral glucose tolerance test; The values are presented as the means ± SEM, n = 12; *P < 0.05 vs. MD10% group; **P < 0.01 vs. MD10% group; ***P < 0.001 vs. MD10% group mRNA expression of these genes in the epididymal fat tissue was not affected by miR-130b-MV treatment. Nevertheless, it remains to be determined whether these genes are affected at the level of protein.
We further investigated the down-stream molecular mechanisms underlying the miR-130b-MV-mediated inhibition in fat deposition. FAS and ACC are key adipogenic enzymes [38] that play pivotal roles in fat deposition, while HSL, ATGL and MGL are important lipases responsible for TG hydrolysis [39,40]. Leptin, a cytokine secreted predominantly from the fat tissue, plays an important role in regulating energy balance, and increased leptin can stimulate lipolysis, by up-regulating HSL, ATGL and MGL expression [41]. In the present study, miR-130b-MV increased HSL, MGL and leptin mRNA expression, but did not influence FAS and ACC mRNA expression. Therefore, it is presumed that miR-130b-MV decreases fat deposition predominantly by enhanced lipolysis but not lipogenesis.
It is noted that miR-130b-MV also altered the expression of other miRNAs related to fat deposition. For instance, miR-378a and miR-378b-3p were up-regulated significantly in the epididymal fat tissue of miR-130b-MV-injected mice. miR-378 is highly induced during adipogenesis and has been reported to be positively regulated in adipogenesis. The role of miR-378 family in fat deposition has been  controversial. Over-expression of miR-378 was shown to increase fat accumulation [42], yet the opposite result was also reported [43]. Over-expression of miR-378 increased lipolysis genes expression, while inhibition of miR-378 expression attenuated stimulated lipolysis and reduced the expression of lipolytic regulators [44]. MVs have been utilized for the delivery of therapeutic RNAi and are considered as a more effective, advantageous method than other options. Compared with the delivery strategies of viruses, lipid nanoparticles and polymeric nanoparticles, MVs present some major advantages. MVs are natural carriers and are not subjected to the attacks by antibodies, complements or opsonins in circulation. Other methods are prone to be cleared or trigger unwanted immune responses [45].
In the present study, MVs delivered miR-130b into the epididymal fat tissue efficiently and repressed the fat deposition, further suggesting that MVs are advantageous carriers for transferring therapeutic small RNAs compared to other methods. However, miR-130b-MV injection was conducted every other day for 10 days due to limited quantity of the miR-130b-MV preparations. The effects and the side-effects, if any, of prolonged treatment of miR-130b-MV remain unclear. It was reported that 7 days after miR-150b-MV injection, miR-150 still maintained at a low level in plasma, and its target gene VEGF was repressed and the tumor development was also suppressed [46]. Future studies are required to test the half-life of MV-protected miR-130b.

Conclusion
In summary, this is the first in vivo study demonstrating that miR-130b-MV can be shuttled into the epididymal fat tissue to down-regulate PPAR-γ expression and to stimulate the expression of lipolysis genes. Further studies may be directed to assess the cytotoxicity and the half-life of miR-130b-MV in the blood, so as to further contribute to the development of anti-obesity drugs for clinical application.

Competing interests
The authors declare that they have no competing interests.
Authors' contributions RZ designed the experiment, supervised the laboratory work and critically revised the manuscript; SF mainly preformed the experiment and analyzed the data; YJ and XY assisted with discussion of results and writing the